Travere Therapeutics (TVTX) Expected to Release Quarterly Earnings on Thursday

Key Points

• Travere Therapeutics is expected to report Q3 2026 results after the market closes on October 29, with analysts projecting a loss of $0.04 per share and revenue of $198.32 million.
• The company’s previous quarter exceeded expectations, reporting a $0.10 per-share loss versus the projected $0.13 loss and revenue of $169.58 million, up 48.2% year over year.
• Analysts maintain a Moderate Buy consensus with an average price target of $69.50, but insiders have sold roughly 1.29 million shares worth $79.5 million over the past three months.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) is projected to issue its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect Travere Therapeutics to announce earnings of ($0.0409) per share and revenue of $198.32 million for the quarter. Individuals can find conference call details on the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:30 PM ET.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.03. The company had revenue of $169.58 million for the quarter, compared to the consensus estimate of $157.27 million. Travere Therapeutics had a negative net margin of 7.35% and a negative return on equity of 55.15%. Travere Therapeutics's revenue was up 48.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.13 EPS. On average, analysts expect Travere Therapeutics to post ($0.92) EPS for the current fiscal year and $2.49 EPS for the next fiscal year.

Travere Therapeutics Trading Up 0.5%

NASDAQ TVTX opened at $52.58 on Thursday. The company has a fifty day simple moving average of $60.89 and a two-hundred day simple moving average of $53.23. The stock has a market cap of $4.96 billion, a P/E ratio of -114.30 and a beta of 1.13. Travere Therapeutics has a 12-month low of $22.59 and a 12-month high of $68.73. The company has a current ratio of 4.05, a quick ratio of 3.99 and a debt-to-equity ratio of 24.58.

Insider Buying and Selling at Travere Therapeutics

In other news, CEO Eric M. Dube sold 243,735 shares of the company's stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $53.82, for a total value of $13,117,817.70. Following the sale, the chief executive officer owned 432,886 shares in the company, valued at $23,297,924.52. This represents a 36.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider William E. Rote sold 112,850 shares of the firm's stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $63.33, for a total value of $7,146,790.50. Following the sale, the insider directly owned 98,197 shares in the company, valued at approximately $6,218,816.01. This trade represents a 53.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 1,294,029 shares of company stock worth $79,454,261. Insiders own 4.44% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on TVTX. Evercore set a $78.00 price objective on shares of Travere Therapeutics in a report on Monday, August 10th. TD Cowen raised their target price on Travere Therapeutics from $60.00 to $75.00 and gave the stock a "buy" rating in a research note on Wednesday, August 5th. Guggenheim raised their target price on Travere Therapeutics from $75.00 to $89.00 and gave the stock a "buy" rating in a research note on Thursday, September 24th. HC Wainwright reaffirmed a "buy" rating and set a $67.00 price target on shares of Travere Therapeutics in a research report on Tuesday, September 22nd. Finally, Canaccord Genuity Group lifted their price target on Travere Therapeutics from $62.00 to $70.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Travere Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $69.50.

About Travere Therapeutics

Travere Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases, with an emphasis on serious kidney conditions. The company's work centers on addressing diseases with limited treatment options and improving outcomes for patients with progressive renal disorders.

Travere's lead commercial product is FILSPARI (sparsentan), an oral treatment for adults with primary immunoglobulin A nephropathy (IgA nephropathy) who are at risk of disease progression.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.